Status:
UNKNOWN
The Efficacy of Hyperthermic Intraperitoneal Chemotherapy to Ovarian Cancer Patients With Homologous Recombination Repair Defect and Residual: a Prospective Cohort Study
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18-70 years
Brief Summary
Ovarian cancer is associated with the highest mortality of all gynecologic cancers. In patients with newly diagnosed advanced ovarian cancer after platinum-containing chemotherapy plus bevacizumab the...
Eligibility Criteria
Inclusion
- Age 18-70 years
- Eastern Cooperative Oncology Group (ECOG) score 0-1
- Adequate kidney function (blood creatinine 58-96µmol/L)
- Adequate haematological function (haemoglobin ≥110g/L, leucocytes ≥4.0×109/L, neutrophils ≥2.0×109/L, platelets≥100×109/L)
- Adequate liver function (serum total bilirubin 3.4-22.2µmol/L, alanine aminotransferase (ALT) 7-40U/L, aspartate aminotransferase (AST) 13-35U/L, AST/ALT ≤1.5
- surgery with residual
- eligible to the maintenance therapy of olaparib plus bevacizumab
Exclusion
- Expected life span ≤8 weeks
- Complicated with any other known malignancies
- Patients with dysfunction of swallow and digestion
- Patients who had received any kind of poly adenosinediphosphate-ribose polymerase（PARP）inhibitor
- refractory hypertension
Key Trial Info
Start Date :
April 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 30 2025
Estimated Enrollment :
310 Patients enrolled
Trial Details
Trial ID
NCT05265117
Start Date
April 1 2022
End Date
March 30 2025
Last Update
February 17 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China